KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

Dallas, TX -- February 1, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a preview presentation scheduled for next week, on Tuesday, February 5^th, to be published on line by KALY CEO Fred Ferri with Professor Jeffry Osbourn, Ph.D., from the University of Kentucky.  In addition to the previously disclosed in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on Chronic Obstructive Pulmonary Disease (COPD) patients, KALY has also competed a long-term, pilot study on the treatment of COPD in primates with its cannabis extracts. The preview on Tuesday next week will elaborate further on the primate study pending a final report on the study coming in March.

Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.  KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.

KALY has licensed its extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of beverages.  With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing.  KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product.  Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCBB: GNBT).  The GNBT product is expected to be on shelves soon.

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
[e-mail]
[phone]